Exelixis, Inc.

EXEL Healthcare Biotechnology

Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.

Revenue
+10.2%
EPS
+22.2%
Free cash flow
−4.83%

Quarter to September 2026, against a year earlier

69.55 0.84 +1.22%
Market cap
$16.8B
P/E
19.9×
Fwd P/E
20.2×
Dividend yield
—
F-score
7/9
Altman Z
12.68
Beneish M
−2.61
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26
Piotroski F-Score

+8 more TTM periods

7 7 7 7
ROE
35.53% 40.99% 44.39% 44.32%
ROA
27.02% 30.69% 33.28% 33.17%
ROIC
49.46% 50.53% 60.45% 66.59%
Return on Tangible Assets
68.85% 89.31% 87.68% 88.78%
Average Days of Receivables
45.14 50.54 48.28 48.02
Free Cash Flow per Share
3.11 3.50 4.62 4.64
Free Cash Flow
844.34 905.17 1,158.19 1,144.49
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026